SpeeDx Receives Clearance for COVID-19 Diagnostic Test
12.8.2021 01:00:00 EEST | Business Wire | Press release
SpeeDx Pty. Ltd. announced today their Plex PCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from a database of over 1,000,000 sequences, the two gene, single-well test detects all current circulating variants§ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. The test is ideally suited to support rapid response to outbreaks, offering scalable 96- or 384-well capacity, automated software reporting, and liquid handling robotics in the form of the SpeeDx Plex Prep™. The combination of Plex Prep™ robotics and automated software analysis can support a scalable workflow for throughputs of 480 to 1,920 patient samples in an 8-hour shift.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005891/en/
The dual-gene, single-well test detects all current circulating variants with scalable capacity - utilising automated software and compatible with liquid handling robotics. Ideal to support surges in test demand with throughputs of up to 1,920 patient samples in an 8 hour shift.
“We have been supporting labs around the world with their COVID-19 testing needs, and we are very happy to extend that service to our local healthcare providers,” said Colin Denver, SpeeDx CEO. “Throughout the pandemic, labs across Australia faced supply challenges from many of the global diagnostic providers, and we are passionate about improving sovereign capacity in this space.”
The addition of Plex PCR® SARS-CoV-2 expands SpeeDx’s respiratory testing menu that includes Plex PCR® RespiVirus* - a two-well multiplex assay for the detection of 14 targets from 11 viral respiratory-illness causing pathogens including Influenza A, Influenza B, and Respiratory Syncytial Viruses (A & B). A respiratory bacteria is also planned to further build SpeeDx’s respiratory infectious disease test portfolio.
SpeeDx recently leveraged their unique mutation detection approach to launch the Plex Prime® SARS-CoV-2 Genotyping portfolio, a range of research reagents supporting laboratory and epidemiological investigations of SARS-CoV-2 newly circulating variants. Investigations connected to Variants of Concern (VOC) show evidence of increased transmissibility, reduced vaccine efficacy, and other attributes that may require specific public health actions.1 There are also emerging Variants of Interest (VOI) appearing in increased proportions or in outbreak clusters. SpeeDx proprietary Plex Prime® and Plex Zyme® technology allows for mutation-specific amplification and detection – a highly sensitive approach that can also simultaneously analyse multiple mutations. Current practices involve multiple-well tests or sequencing analysis, all of which extend the turn-around-time to result. SpeeDx advanced multiplex technology reduces the number of wells required, resulting in a simplified process with increased throughput to accelerate turnaround of variant investigations.
The addition of Plex PCR® SARS-CoV-2 and associated products broadens SpeeDx’s available testing menu from the current suite of tests for sexually transmitted infections and antimicrobial resistance markers that include Resistance Plus ® MG† and Resistance Plus ® GC† – supporting Resistance Guided Therapy for Mycoplasma genitalium and gonorrhoea respectively – and Plex PCR® VHS†, a multiplex lesion diagnostic test.
*not available in the U.S.
§based on in silico investigation as of August 2021
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
References
- Centers for Disease Control and Prevention, SARS-CoV-2 Variant Classifications and Definitions. found at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html last updated May 17, 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005891/en/
Contact information
Global Marketing Director
Madeline O’Donoghue
madelineo@speedx.com.au
+61 406 582 808
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB Group Unveils its Long-Term Vision “OPEN FRONTIER 2035”3.2.2026 15:00:00 EET | Press release
JTB Group has unveiled “OPEN FRONTIER 2035,” its long-term vision for the next decade. The vision positions JTB as a frontier (leading-edge) enterprise that brings together people, places, businesses, and possibilities to create connections and generate new value for society. By pioneering a new era of Designing Human Moments, we will harness our expertise and insights to connect, create, and contribute to the world—enriching people’s lives with excitement and contentment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203174455/en/ JTB Group's Desired Vision for 2035 Our Source of Value is the Power to Create Connections JTB Group has positioned “Intelligence that Creates Connections” as the core of its competitive advantage. Insight and expertise—when combined and continuously enhanced—will enable the Group to create meaningful connections by bringing together people, places, businesses, and possibilities, thereby gener
Visa Direct and UnionPay International Will Extend Global Money Movement Network to Billions of Cards in Chinese Mainland3.2.2026 14:00:00 EET | Press release
At Web Summit Qatar, Visa (NYSE:V) and UnionPay International (UPI) announced an agreement to enable cross-border money movement into Chinese Mainland through Visa Direct. Once fully rolled out, clients will be able to send cross-border remittances and business-to-consumer payouts to more than 95 percent of UnionPay International debit cardholders in Chinese Mainland, through a single connection. By connecting Visa Direct’s global money movement network to UPI’s MoneyExpress platform, Visa will provide a more seamless, secure, and transparent way for consumers and businesses worldwide to send money into Chinese Mainland, one of the world’s largest remittance destinations. This milestone showcases Visa’s commitment to opening global corridors and extending reliable money movement capabilities to people and businesses worldwide. “Global business now moves at internet speed, but money hasn’t always kept pace,” said Vira Platonova, Global Head of Visa Direct. “By expanding Visa Direct’s re
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®3.2.2026 14:00:00 EET | Press release
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval. “This approval represents a step toward more personalized and effective cancer treatment in China,” says Alok Sharma, Global Clinical Market Director at Promega. “We are proud to collaborate with pharmaceutical companies to deliver global solutions that expand access to innovative technologies and life-saving, effective therapies.” China continues to face one of the world’s highest cancer burdens, with solid tumors representing the vast majority of diagnoses nationwide. Despite advances in oncology care, most patients with advanced so
Rising Global Bullion Market Risks Are Forcing European Investors to Rethink Physical Gold Access3.2.2026 11:35:00 EET | Press release
As volatility reshapes global financial markets, European institutional investors are turning to safe-haven assets. While physical gold remains one of the world's most resilient and attractive store-of-value assets, secure and verifiable access to bullion has become increasingly difficult. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203826775/en/ Illustrative image of physical gold bullion bars. (Photo: AETOSWire) Recent industry developments have placed structural pressure on the gold market. Elevated price levels have heightened concerns around counterfeit bars, fragmented supply chains, and the complexity of cross-border custody. For European institutions operating under strict regulatory oversight, the challenge is no longer whether to allocate to gold — but how to do so safely, transparently, and within established compliance frameworks. To this end, Golden Ark Reserve, operated by Golden Ark General Trading (FZC)
Hyper-Personalization at Scale: Why Brands Must Shift to an Agentic AI Strategy3.2.2026 11:00:00 EET | Press release
Global AI-first cloud communications platform Infobip, celebrating two decades of innovation, predicts an imminent and seismic shift in brand-consumer engagement. Moving away from the current application-to-person (A2P) messaging, Infobip forecasts a widespread shift to an agent-to-person model, eventually leading to a fully autonomous agent-to-agent future by 2030. The Evolution of Engagement Swift AI adoption is driving enterprises toward agentic AI communication models, which drive autonomous customer communications across all touchpoints. This technology enables hyper-personalization across multiple channels, creating highly engaging content tailored to individual needs. Silvio Kutić, Infobip CEO, comments: “How we communicate with brands is constantly evolving. In this new agentic AI world, brands must seize the opportunity to take a holistic approach to communication. They must capitalize on the hyper-personalization made available through agentic AI and rich communication channe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom